







WHO Critical Priority *Escherichia coli* as One Health Challenge for a Post-Pandemic Scenario: Genomic Surveillance and Analysis of Current Trends in Brazil

Bruna Fuga,^{a,b,c} Fábio P. Sellera,^{c,d,e}  Louise Cerdeira,^{a,f,g} Fernanda Esposito,^{b,c} Brenda Cardoso,^{a,c}  Herrison Fontana,^{b,c} Quézia Moura,^{a,c,h} Adriana Cardenas-Arias,^{a,c} Elder Sano,^{a,c} Rosineide M. Ribas,ⁱ Albalúcia C. Carvalho,^j Maria Cristina B. Tognim,^k Marcia Maria C. de Morais,^l Ana Judith P. G. Quaresma,^m Ângela Patrícia Santana,ⁿ Joice N. Reis,^o Marcelo Pilonetto,^p Eliana Carolina Vespero,^q  Raquel R. Bonelli,^r Aloysio M. F. Cerqueira,^s Thais C. M. Sincero,^t  Nilton Lincopan^{a,b,c}

^aDepartment of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil

^bDepartment of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil

^cOne Health Brazilian Resistance Project (OneBR), São Paulo, Brazil

^dDepartment of Internal Medicine, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, Brazil

^eSchool of Veterinary Medicine, Metropolitan University of Santos, Santos, Brazil

^fDepartment of Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia

^gDepartment of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK

^hFaculty of Health Sciences, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil

ⁱLaboratory of Molecular Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil

^jClinical Laboratory, Federal University of Paraíba, João Pessoa, Paraíba, Brazil

^kSchool of Pharmacy, State University of Maringá, Maringá, Brazil

^lInstitute of Biological Sciences, University of Pernambuco, Recife, Brazil

^mLaboratory of Special Pathogen Infections, Bacteriology and Mycology, Evandro Chagas Institute, Ananindeua, Brazil

ⁿFaculty of Agronomy and Veterinary Medicine, University of Brasília, Brasília, Brazil

^oFaculty of Pharmacy, Federal University of Bahia, Salvador, Brazil

^pCentral Laboratory of the State of Paraná-LACEN, São Jose dos Pinhais, Brazil

^qMicrobiology Laboratory of the University Hospital of Londrina, State University of Londrina, Londrina, Brazil

^rMedical Microbiology Research Laboratory, Paulo de Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

^sLaboratory of Enteropathogens, Veterinary and Food Microbiology, Biomedical Institute, Fluminense Federal University, Niterói, Brazil

^tLaboratory of Applied Molecular Microbiology, Department of Clinical Analysis, Federal University of Santa Catarina, Florianópolis, Brazil

ABSTRACT The dissemination of carbapenem-resistant and third generation cephalosporin-resistant pathogens is a critical issue that is no longer restricted to hospital settings. The rapid spread of critical priority pathogens in Brazil is notably worrying, considering its continental dimension, the diversity of international trade, livestock production, and human travel. We conducted a nationwide genomic investigation under a One Health perspective that included *Escherichia coli* strains isolated from humans and non-human sources, over 45 years (1974–2019). One hundred sixty-seven genomes were analyzed extracting clinically relevant information (i.e., resistome, virulome, mobilome, sequence types [STs], and phylogenomic). The endemic status of extended-spectrum β -lactamase (ESBL)-positive strains carrying a wide diversity of *bla*_{CTX-M} variants, and the growing number of colistin-resistant isolates carrying *mcr*-type genes was associated with the successful expansion of international ST10, ST38, ST115, ST131, ST354, ST410, ST648, ST517, and ST711 clones; phylogenetically related and shared between human and nonhuman hosts, and polluted aquatic environments. Otherwise, carbapenem-resistant ST48, ST90, ST155, ST167, ST224, ST349, ST457, ST648, ST707, ST744, ST774, and ST2509 clones from human host harbored *bla*_{KPC-2} and *bla*_{NDM-1} genes. A broad resistome to other clinically relevant antibiotics, hazardous heavy metals, disinfectants, and pesticides was further predicted. Wide virulome associated with invasion/adherence, exotoxin

Editor William Lainhart, University of Arizona/
Banner Health

Copyright © 2022 Fuga et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Bruna Fuga, bruna.fuga@hotmail.com, or Nilton Lincopan, lincopan@usp.br.

The authors declare no conflict of interest.

Received 22 August 2021

Accepted 19 January 2022

Published 2 March 2022

and siderophore production was related to phylogroup B2. The convergence of wide resistome and virulome has contributed to the persistence and rapid spread of international high-risk clones of critical priority *E. coli* at the human-animal-environmental interface, which must be considered a One Health challenge for a post-pandemic scenario.

IMPORTANCE A One Health approach for antimicrobial resistance must integrate whole-genome sequencing surveillance data of critical priority pathogens from human, animal and environmental sources to track hot spots and routes of transmission and developing effective prevention and control strategies. As part of the Grand Challenges Explorations: New Approaches to Characterize the Global Burden of Antimicrobial Resistance Program, we present genomic data of WHO critical priority carbapenemase-resistant, ESBL-producing, and/or colistin-resistant *Escherichia coli* strains isolated from humans and nonhuman sources in Brazil, a country with continental proportions and high levels of antimicrobial resistance. The present study provided evidence of epidemiological and clinical interest, highlighting that the convergence of wide virulome and resistome has contributed to the persistence and rapid spread of international high-risk clones of *E. coli* at the human-animal-environmental interface, which must be considered a One Health threat that requires coordinated actions to reduce its incidence in humans and nonhuman hosts.

KEYWORDS Enterobacterales, resistome, virulome, high-risk clones, One Health, multidrug resistance, carbapenems, colistin, carbapenemases, ESBL, MCR, genomic surveillance, South America

Antibiotic resistance is an ever-growing threat that contributes to serious adverse consequences, such as therapeutic failure, economic burden, and increased mortality rates worldwide (1, 2). In this regard, the multisectoral (human, animal, and agriculture) overuse of important antimicrobial drugs has been considered the main driver of the multidrug resistance phenomenon (3). In an attempt to overcome this global public health challenge, the World Health Organization (WHO) has provided a red alert for "Highest Priority Critically Important Antimicrobials" (i.e., broad-spectrum cephalosporins, carbapenems, and polymyxins), as well as insights about emergent critical-priority pathogens, including *Escherichia coli* (2, 4).

The epidemiological success of multidrug-resistant (MDR) *E. coli* has been described in a range of host/source scenarios, where high-risk pandemic lineages (e.g., ST10, ST38, ST58, ST69, ST131, ST155, ST167, ST393, ST405, ST648, and ST410) took the lead with remarkable epidemiological relevance (5–8). In this regard, genomic versatility of these clones has enhanced their pathogenicity and competence to survive for long periods (9). In addition, their ability to transfer genetic determinants by mobile genetic elements (MGEs) has been responsible for substantial contributions to spread clinically relevant resistance genes, including those encoding resistance to colistin (*mcr*), carbapenems (e.g., *bla*_{KPC}, *bla*_{NDM}), cephalosporins (e.g., *bla*_{CTX-M}) and fluoroquinolones (e.g., *qnr*, *aac*[6′]-*lb-cr*), among others (7).

To mitigate these challenges, an interdisciplinary One Health approach has been encouraged to prevent and combat the emergence and dissemination of antibiotic resistance interlinking humans, animals, and their shared environments (10). Herein, we performed a One Health surveillance using microbiological methods and whole-genome sequencing (WGS) to provide an up-to-date scenario of the epidemiology, antimicrobial-resistance profile, genomic features, phylogenetic relationship, and patterns of *E. coli* recovered from the human-animal-environmental interface in Brazil, the largest country in Latin America.

RESULTS

One Health background of *E. coli* strains. *E. coli* genomes investigated included 167 strains from human-animal-environment interface circulating in 40 Brazilian cities, and 16 states with highest population density (North: Pará and Tocantins states; Northeast: Paraíba, Pernambuco, Ceará, Sergipe, Rio Grande do Norte and Bahia states;

Midwest: Goiás and the Federal District states; Southeast: Minas Gerais, São Paulo, and Rio de Janeiro states; South: Paraná, Santa Catarina, and Rio Grande do Sul states).

These strains have been collected between 1974 and 2019, and included humans ($n = 85$), animals ($n = 42$: dog, cat, cattle, chicken/poultry, horse, turkey, anteater, elephant, fish, owl, ocelot, penguin, and vulture), food ($n = 15$: chicken, shrimp, mussels, oysters, spinach, and cabbage) and environmental ($n = 25$: freshwater, seawater, soil, drainage, and directional residue) sources (Table S1). The strains were selected according to resistance profile; included 54 genomes sequenced in this project and 113 sequences available in public databases.

The 54 *E. coli* strains screened in this study displayed resistance to clinically relevant fluoroquinolones, aminoglycosides, colistin, broad-spectrum cephalosporins and/or carbapenems, of which 42 were classified as multidrug-resistant strains (Fig. 1).

***E. coli* clones belonging to pandemic sequence types (STs).** Among 167 genomes of *E. coli* strains circulating at the human-animal-environmental-food interface (from humans; pets: dog and cat; livestock animals: cattle, chicken/poultry, horse, and turkey; wild animals: anteater, elephant, fish, ocelot, owl, penguin, and vulture; meat: chicken; crustacean: shrimp; seafood: mussels and oysters; vegetables: spinach and cabbage; freshwater; seawater; soil; drainage; and directional residue) in all regions of Brazil (Fig. 2A), we identified 69 different multilocus sequence types, in addition to 4 novel STs. The dissemination of international clones ST10, ST38, ST117, ST131, ST224, ST354, ST410, ST457, ST648, and ST744 was confirmed (Fig. 2B). Most common STs associated with human hosts were ST131, ST410, and ST354, whereas those associated with animal hosts were ST131 and ST648. On the other hand, ST38 and ST10 were the most predominant among food and environmental strains. Dominant overlaps in STs shared by all reservoirs/hosts (human, animal, food, and environmental) were associated with ST131 and ST648, which represent 11.4% ($n = 19$) and 5.4% ($n = 9$) of all strains, respectively.

Broad resistome among MDR *E. coli* strains circulating at the human-animal-environment interface. The resistome (antibiotics, heavy metals, pesticide, and disinfectants) of the 167 *E. coli* analyzed is quoted in the Fig. 3. In brief, *bla*_{CTX-M} (52.7%) and *bla*_{TEM}-type (53.9%) were the predominant β -lactam resistance genes, regardless of the source and origin. In this regard, a high occurrence of *bla*_{CTX-M}-type genes in food (73.3%), animal (69.0%), environment (60.0%), and human samples was confirmed, with *bla*_{CTX-M-2}, *bla*_{CTX-M-8} and *bla*_{CTX-M-15} variant being widely disseminated. Otherwise, *bla*_{KPC-2} (4.2%), *bla*_{NDM-1} (3.6%), and *bla*_{IMP-1} (0.6%) carbapenemase genes were only predicted in human isolates. Genes *bla*_{OXA}- (17.4%) and *bla*_{CMY-2}-type (10.2%) were also identified among the 167 *E. coli* genomes analyzed. Of concern, *mcr*-type colistin resistance genes (*mcr-1.1*, *mcr-1.5*, *mcr-5.1*, *mcr-5.3*, and *mcr-9* variants) were detected in 35 *E. coli* genomes (21.0%) of human, animal, environmental and food isolates.

The presence of plasmid-mediated quinolone resistance (PMQR) [*qnrA* (2.4%), *qnrB1* (1.2%), *qnrB2* (2.4%), *qnrB19* (11.4%), *qnrS* (4.2%)], *aac(6')-Ib-cr* (17.9%), and *qepA4* (0.6%) genes was also predicted. Although the *aac(6')-Ib-cr* gene was mostly found in isolates from human hosts (70%), it was also detected in animal (13.3%), food (13.3%), and environmental (3.3%) *E. coli* genomes. The *qnrB* genes were present in *E. coli* genomes from all ecological scenarios surveyed, whereas *qepA4* was only found in human isolates. Quinolone resistance was also mediated by mutations (*gyrA*-S83L, *gyrA*-D87N, *gyrA*-D87Y, *gyrA*-D87G, *gyrA*-D87V, *parC*-S80L, *parC*-A56T, *parC*-S80R, *parC*-E84K, *parC*-E84V, *parC*-E84G, *parE*-S458A, *parE*-S458T, *parE*-I355T) in the quinolone resistance determining region (QRDRs), in both human and nonhuman strains.

Aminoglycoside [*aad*, *aph(3')*, *aph(3'')-Ib*, *aph(4)-Ia*, *aph(6)*, *aac(6')*, *ant(2'')-Ia*, and *rmtD*], trimethoprim (*dhfrA*), tetracycline (*tet*), fosfomicin (*fosA3*), phenicol (*cmiA1*, *catA1*, *catB3*, and *flor*), sulfonamide (*sul*), macrolide (*mph*, *erm*, *mef*, *inu*, and *msr[E]*), and rifampicin (*arr-3*) resistance genes were also predicted, as summarized in Fig. 3.

Genes conferring resistance to heavy metals (arsenic, $n = 166/167$; silver, $n = 42/167$; mercury, $n = 60/167$; and tellurium, $n = 16/167$), QAC disinfectants ($n = 167/167$), and pesticide (glyphosate, $n = 167/167$) were identified in *E. coli* isolates from all surveyed hosts and reservoirs. In contrast, tellurium resistance genes (*terC* and/or *terD*)




FIG 1 Heatmap showing the antimicrobial resistance profile of 54 *Escherichia coli* strains from Brazil. Boxes in dark red represent the antibiotics to which the strains exhibited a resistance profile, whereas boxes in light red represent susceptible profiles. Additionally, boxes in light pink illustrate the antibiotics that have not been tested. Antibiotic classes are abbreviated as follows: meropenem (MER), ertapenem (ETP), imipenem (IPM), ceftazidime (CAZ), cefotaxime (CTX), nalidixic acid (NAL), ciprofloxacin (CIP), amoxicillin/clavulanate (AMC), aztreonam (ATM), amikacin (AMI), gentamicin (GEN), trimethoprim-sulfamethoxazole (SXT), enrofloxacin (ENO), chloramphenicol (CHL), fosfomycin (FOS), cephalothin (CEP), ceftiofur (CTF), ampicillin (AMP), and tetracycline (TET). The colistin (COL) resistance was determined by the broth microdilution method.




FIG 2 (A) Geographic distribution of *Escherichia coli* strains ($n = 167$) circulating at the human-animal-environmental-food interface in all regions of Brazil (North, Northeast, Midwest, South, and Southeast). North: PA (Pará), TO (Tocantins); Northeast: BA (Bahia), CE (Ceará), RN (Rio Grande do Norte), PB (Paraíba), PE (Pernambuco), SE (Sergipe); Midwest: DF (Distrito Federal), GO (Goiás); Southeast: MG (Minas Gerais), RJ (Rio de Janeiro), SP (São Paulo); and South: PR (Paraná), SC (Santa Catarina), and RS (Rio Grande do Sul). The map was created using an online service (<https://mapchart.net/>). (B) Representation of major international clones circulating in Brazilian regions.

were not identified in food strains, whereas no lead resistance genes were detected in this study. Detailed resistome information is also shown in Table S1.

Mobilome analysis. The investigation using CGE - Center for Genome Epidemiology - tool, showed that the plasmid population of *E. coli* lineages was diverse, with the most common incompatibility group being IncFIB/IncFIB-like (52%), followed by IncFII/IncFII-like (33.5%), IncI/IncI-like (31.1%), IncFIA/IncFIA-like ($n = 25.7%$), Col/Col-like (21.5%), and IncX4 (20.9%). Additionally, 129 (77.2%) *E. coli* genomes presented more than one plasmid replicon type. *E. coli* genomic sequences that presented IncF (FAB type), IncI1, IncN, IncA/C, IncHI1, and IncHI2 replicons were also evaluated for plasmid MLST (pMLST), as shown in Fig. 4. We observed specific pMLST allele sequences according to the bacterial source. On the other hand, some subtypes (A1 and A4 allelic variant from IncFIA plasmid; B1 and B49 from IncFIB plasmid; F2, F24, F18, F33 from IncFII plasmid; 113 and 3 from IncI plasmid) were found regardless of the source of origin.




FIG 3 Heatmap displaying the resistome and plasmidome of *Escherichia coli* strains considering the ST, region, and source features. The colored regions in different shades of blue represent the presence of (1) antibiotic resistance genes (β -lactams, phenicol, colistin, tetracyclines, glycopeptides, aminoglycosides, fosfomycin, trimethoprim, macrolides, quinolones, sulfonamides, and rifampin class); (2) mutation in the quinolone resistance determining region (QRDRs) and/or *pmrB* gene; (3) metals, biocides (QACs) and pesticide (glyphosate) resistance genes; and (4) plasmid incompatibility group (Inc.); while blank fragments represent their absence.

Virulome analysis. The virulome context of *E. coli* strains is quoted in Fig. 5. In an effort to better understand the virulome scenario, the genes were grouped into the following key components: (i) adherence, (ii) autotransporter, (iii) invasion, (iv) toxins, (v) bacteriocins, (vi) iron uptake, (vii) secretion systems, (viii) protectins/serum resistance,




FIG 4 Venn diagram displaying plasmidial MLST (pMLST) dynamics in the One Health context.

and (ix) other factors of pathogenicity. The predominant adherence-associated genes were *ecp* (96.5%), *fim* (93.4%), and *lpfA* (52.7%), whereas genes encoding toxins were *hly* (37.7%), *astA* (10.8%) and *sat* (9.6%). The main genes involved in protectins/serum resistance were *traT* (73.1%), *omp* (71.3%) and *iss* (64.7%); and the identified iron acquisition system (siderophores) genes were *ent* (65.3%), *sitA* (55.7%), *iutA* (47.3%), *iucC* (46.1%), *ybt* (43.1%), *fyuA* (43.1%), and *irp* (41.9%). For the secretion system, the presence of the *tss* gene was highlighted, whereas the *gad* (glutamate decarboxylase) gene, which contribute to acid resistance was also identified. Others virulence genes, including *aap*, *daa*, *fae*, *f17*, *eatA*, *pet*, *ltcA*, *elt*, *ccl*, *celb*, *icsB*, *ipa*, *ipg*, *osp*, *mxi*, *spa*, *virA*, *grt*, *sigA*, and *tccp* occurred only in single strains (Table S1).

An extensive virulome (≥ 90 virulence genes) was predicted in genomes of lineages ST127 (phylogroup B2, O6:H131) and ST73 (phylogroup B2, O6:H1), identified in human and animal hosts. Strains collected before the 2000s (2012-1, 2531-13, 3522-6, BH100, and BH100L), showed broad virulome (on average 58 genes), and resistance genes to β -lactam (*bla*_{TEM}, *bla*_{OXA}), phenicol (*catA1*), tetracycline (*tet[B]*), trimethoprim (*dfrA*), sulfonamide (*sul1*), and aminoglycoside (*aadA1* and *aph[3']-Ia*).

Regarding classification of type 1 fimbria (*fimH*) and serotyping, 38 distinct *fim* types and diverse serotypes were found, where Clermont typing showed that phylogroups A (25.7%) and B1 (25.1%) were predominant (Fig. 5).

Phylogenomics and evolutionary dynamics of human and nonhuman *E. coli* clones. The SNP maximum likelihood tree of human and nonhuman *E. coli* genomes, constructed using RAxML-NG (100 bts), is presented in Fig. 6. Strikingly, *E. coli* lineages from distinct sources (human, animal, environmental and food) and geographic regions, in Brazil, were closely related in the phylogenetic tree, being grouped in clades. Pangenome and SNP matrix data are quoted in Fig. S1 and, Table S2 and S3.

A zoom-in on the representative clades of important pandemic clones depicted in the phylogenetic tree is shown in Fig. 7. In this regard, *E. coli* strains belonging to the ST10, collected in the Southeast and Midwest regions of Brazil, were nested within a human, animal, and environmental clade. ST10 has been a persistent One Health clone, present in this country since at least 1989. The ST10 clade included strains carrying *bla*_{CTX-M-8} (ONE69 and ONE88), *bla*_{CTX-M-1} and *mcr-1.1* (ICBEC7P and ICBEC13AM), and *bla*_{CMY-2} (ONE39) resistance genes (Fig. 7A and Table S3).

For the ST38 clone, phylogenetic tree revealed a clade that included strains isolated from food (mussels, chicken meat, cabbage), birds of prey (vulture), and environmental (seawater) samples (Fig. 7B). ST38 has been present since at least 2016, at the Southeast




FIG 5 Schematic representation of virulome, sequence type, *fimH* type, and Clermont phylogroup of Brazilian *Escherichia coli* strains indicated as per the legend. Not determined (-).

and North regions of the country. Specifically *E. coli* strains ONE97 and ONE96, isolated from birds of prey in 2017, were closely related (>98% identity) to the environmental ONE86 strain isolated in 2016, from a seawater sample at the same region; and carried an identical resistome, including the *bla*_{CTX-M-14} extended-spectrum β -lactamase (ESBL)-gene.

For the international ST131 clade, most strains presented a broad and critical resistome that included *bla*_{CTX-M-8}, *bla*_{CTX-M-9}, *bla*_{CTX-M-15} and *bla*_{CTX-M-27} ESBL genes. These strains have been identified from 2010, highlighting the rapid dissemination of this international high-risk clone over the last decade (Fig. 7C, Table S3). A multiplicity of




FIG 6 Phylogenetic tree based on the core genome (1793 genes) of the 167 Brazilian *Escherichia coli* strains circulating at the human-animal-environmental-food interface. The figure was generated with iTOL version 5.6.1 (<https://itol.embl.de>), and the interactive version of this tree can be found at <https://microreact.org/project/noM6Wi46mnpdYSzENnWmKX>. Phylogenetic tree was rooted at midpoint. The ST10 clade includes isolates belonging to ST10 (*adh-10*, *fumC-11*, *gyrB-4*, *icd-8*, *mdh-8*, *purA-8*, *recA-2*), the closely single locus variants (SLV) ST11010 (*icd-1290*), ST752 (*recA-49*) and ST167 (*purA-13*), and double locus variants (DLV) ST378 (*icd-1*, *purA-66*) and ST617 (*purA-8*, *recA-73*).

origins and geographic features among these strains denoted One Health implications. All strains displayed a virulome contributing to adherence, invasion, toxins production, iron uptake, and protectins/serum resistance.

The phylogenomic analyses of ST354 showed a clade with strains presenting the broadest set of virulence determinants, which have been circulating at the human-environmental interface from 2016 (Fig. 7D and Table S3). From the resistome perspective, all human *E. coli* ST354 strains carried the *mcr-1.1* gene; with ONE46, EW239 and ONE78 strains being more closely related (>99% identity).

Lineages of ST410 have been identified at the human-animal interface in North, Northeast and Southeast regions of Brazil, from 2014. Phylogenomics revealed that




FIG 7 Zoom-in depicting a maximum-likelihood (ML) phylogenetic tree built using core genome single-nucleotide polymorphisms (SNPs) of *E. coli* lineages (A-ST10, B-ST38, C-ST131, D-ST354, E-ST410, F-ST648, and G-ST744). The phylogeny was tested against 100 bootstrap replications and the image was visualized using iTOL version 5.6.1 (<https://itol.embl.de>). The panel on the right represents the geographic region and the resistome and virulome context.

while ONE50, ONE51 and ONE52 human strains shared 99.9% identity (Fig. 7E and Table S3) and an identical resistome and virulome, A240 and A241 (animal hosts) and BR12-DEC (human host) strains shared >93% identity.

Phylogenomic investigation also confirmed that the high-risk ST648 clone has been another closely related pandemic lineage with One Health implications in this country

(Fig. 7F), from at least 2013, when the first *bla*_{KPC-2}-positive *E. coli* strain (1326F) belonging to this clone was isolated from a human host in Southern Brazil (Table S3). In the phylogenetic tree, the 1326F strain was closely related to the ONE111 *bla*_{CTX-M-15}-positive *E. coli* strain isolated from a food sample collected in 2016, in the Southeast region. Moreover, from core genome SNPs analysis, WHO critical priority EW222 (*bla*_{CTX-M-15}), 7469 (*bla*_{CTX-M-15}, and *bla*_{IMP-1}) and ONE16 (*bla*_{CTX-M-15}, and *bla*_{KPC-2}) strains isolated from environmental and human samples collected in the Northeast, Southeast and South regions, shared >99% identity (Fig. 7F and Table S3).

Finally, *E. coli* strains belonging to ST744 were clustered within a human-animal clade that included strains circulating in different geographical regions, since at least 2014 (Fig. 7G and Table S3). In this regard, the first strain belonging to this lineage was isolated from a human host and carried *bla*_{KPC-2} and *mcr1.1* genes, being closely related to the ONE41 (*bla*_{CTX-M-1}- and *bla*_{CMY-2}-positive) human strain identified in 2015, at the Southeast region. Interestingly, ONE27 (*bla*_{NDM-1}-positive) and ONE82 (*bla*_{CTX-M-2}-positive) strains were isolated from human and a fish samples at the South and Southeast regions, respectively; sharing 98.1% identity in the phylogenetic tree (Fig. 7G).

DISCUSSION

Brazil is the largest and most populated country in South America, with a wide geographical area that comprises different ecosystems with a remarkable biodiversity (11). Unfortunately, in most metropolitan areas of this country antimicrobial resistance has been a critical issue, not restricted to hospital settings (5). In fact, in the last years, there has been growing concern that the nationwide propagation of antibiotic resistance is also associated with environmental reservoirs that are linked to anthropogenic activities such as animal husbandry, agribusiness activities and wastewater treatment. In this study, we performed a genomic-based surveillance using a One Health approach, elucidating the genomic background of *E. coli* strains recovered from the human-animal-food-environmental interface over the past 45 years. Our findings highlight (i) a broad antimicrobial resistance, (ii) convergence of virulence and resistance genes, (iii) successful expansion of international high-risk clones, and (iv) phylogenomic diversity with strains isolated from human and nonhuman samples clustering together.

The resistance suggests that ESBL endemicity has been associated with β -lactamases conferring resistance to ceftiofime, where CTX-M-positive *E. coli* have been identified in humans, vegetables, chicken meat, wild and food-producing animals, pets, Amazonian fish, and aquatic environments (12–19). In our study, we found the predominance of *bla*_{CTX-M-15}, followed by *bla*_{CTX-M-2}, and *bla*_{CTX-M-8} ESBL genes. Interestingly, food samples were identified as potential reservoirs associated with *bla*_{CTX-M}-type genes, whereas it is well documented that food-producing animals play an important role as a reservoir of MDR pathogens (20). In line with this, the hypothesis has been suggested that the commercial chicken meat could be a reservoir of *E. coli* strains co-harboring *bla*_{CTX-M} and colistin resistance *mcr-1* genes (21).

The overuse of colistin as a growth promoter in food-producing animals and its clinical usage to treat carbapenem-resistant infections has been a red alert to global health (22–24). We found several strains from all sources (human, animal, food, and environmental) surveyed harboring *mcr*-type genes, including those belonging to international sequence types ST10, ST131, ST354, ST393, ST410, and ST744. Main plasmids that have driven the spread of the *mcr-1* genes have belonged to IncX4, IncI2, and IncHI2 incompatibility groups (23, 25). Here, the presence of IncX4 plasmid replication gene was confirmed in 82.8% of *mcr*-positive strains, which reinforces the endemicity of this plasmid type within a One Health perspective.

The rapid spread of *bla*_{KPC-2}-positive carbapenem-resistant *E. coli* strains during the last years is another epidemiological data observed in this study, which also requires closer attention, particularly due to its association with international high-risk clones ST90, ST224, ST648 and ST744 (5, 7, 26). Although, there has been concern around *bla*_{KPC} in *E. coli* of ST131, another globally disseminated and clinically successful clone

(27), here this lineage was only associated with the presence of *bla*_{CTX-M-8r}, *bla*_{CTX-M-9r}, *bla*_{CTX-M-15r}, *bla*_{CTX-M-27} and *bla*_{CMY-2} β -lactamase genes.

Another point that deserves attention is the rate of quinolone resistance related to chromosomal mutations and/or PMQR genes. Quinolone resistance has not been limited to health care-associated infections. In this study, approximately 37% of strains, including those from human, animal, food, and environmental sources/host presented one or more quinolone resistance genes, whereas 64% of the total had at least one mutation, confirming a worldwide trend, where the presence of quinolone-resistant *E. coli* strains has been found in a wide range of human and nonhuman reservoirs (5, 7, 27–32).

Our findings also reveal that the resistome of the screened *E. coli* strains extends to heavy metals, biocides, and pesticides, which could contribute for the development of coresistance to antibiotics and other antimicrobial agents (33). This should be considered a critical problem since biocides are agents for disinfection commonly used in domiciliary, veterinary and hospital settings (33). Common active ingredients in disinfectants are quaternary ammonium compounds (QACs), of which benzalkonium chloride is a concern because of its widespread use combined with environmental impacts (34). Disinfectants containing quaternary ammonium compounds, including benzalkonium chloride (BAC), act mainly by disturbing the integrity and function of the cell membrane that leads to cell death. Since bacterial resistance to BAC compounds is based on overexpression of efflux pumps, QAC-induced overexpression of efflux pumps can lead to: i) cross-resistance for clinically relevant antibacterial agents, including fluoroquinolones; ii) stress response facilitating mutation in the Quinolone Resistance Determining Region; iii) biofilm formation increasing the risk of transfer of mobile genetic elements carrying fluoroquinolone or QAC resistance determinants (35). Once benzalkonium chloride enters the environment, it can be lethal to aquatic organisms contributing to antimicrobial resistance. As well as for antibiotic residues, environmental entry of QACs is through wastewater effluent and sewage. Therefore, the dissemination of antibiotic resistance and *qac* genes among *E. coli* strains circulating across clinical boundaries could be a direct consequence of anthropogenic activities (36).

Convergence of resistance and virulence in *E. coli* lineages is another issue that has worried the medical community (37). Indeed, virulence potential of ESBL- and/or AmpC- β -lactamase-producing *E. coli* strains from healthy food animals from Europe and South America has been recently documented (38–39). In our study, virulence factors involved in adherence and biofilm (e.g., *afaA*, *faeC*, *fimC*, *focX*, *hra*, *iha*, *pap*, and/or *sfa* genes) were remarkably shared, mainly by the international high-risk clones identified. Previous analysis on the distribution of adherence/biofilm genes in *E. coli* lineages has highlighted the presence of these genes in strains belonging to ST131 and ST648 clones (40).

Regarding protectins/serum resistance genes, most *E. coli* strains (59.9%) were positive for *traT*, *omp*, and *iss* genes. The *iss* gene plays a role on microbial survival to serum due to the phagocytosis protection factor; *omp* (outer membrane protein) gene is associated with evasion of the body's defense allowing intracellular survival, whereas *traT* gene is involved in the inhibition of complement system activity (41).

Siderophores (high-affinity iron chelating molecules) have been received special attention as essential virulence factors of bacteria, acting as a toxin and/or modulator of the immune system of the host (42–45). Strains that can produce more siderophores are considered highly virulent (45). In this study, more than 40% *E. coli* strains also carried siderophore (aerobactin, yersiniabactin, salmochelin, and enterobactin)-encoding genes. Additionally, we predicted clinically relevant virulence genes encoding hemolysin, enteroaggregative heat-stable toxin, secreted autotransporter toxin, cytotoxic necrotizing factor 1, serine protease autotransporter, and vacuolating autotransporter toxin (41, 46).

E. coli have been grouped into eight major phylogroups (i.e., A, B1, B2, C, D, E, F and G) based on genetic analyses. While A and B1 phylogroups are widely associated with commensal lineages, B2 has been a predominant pathogenic lineage. Additionally,

strains from phylogroup B1 have been found to persist longer and to tolerate lower temperatures than the remaining phylogroups, resulting in higher ability to colonize aquatic ecosystems than A and B2 phylogroups, which have been linked to an animal-associated lifestyle (47). Many recognized virulence factors are enriched among lineages belonging to specific phylogroups of *E. coli* that are evolutionarily quite old, globally distributed, and commonly inhabiting healthy human guts, such as phylogroup B2. In this study, Clermont phylotyping analysis confirmed that strains carrying the colibactin gene *clbB* belong to phylogroup B2, as previously reported (48). On the other hand, some lineages of *E. coli* B2 carried the broadest virulome. In this way, it has been suggested that strains B2 have been commonly responsible for extraintestinal infections and possess numerous virulence genes (17, 37, 41). The occurrence of clinically relevant resistance genes (e.g., *bla*_{CTX-M} and *bla*_{KPC}) was observed in strains belonging to A and B1 phylogroups, which presented a smaller set of virulence genes, as previously reported (37, 41, 49, 50).

Among international clones predicted ST131-B2 presented *fimH30* and *fimH22* alleles. The *fimH30* appears to be the most prevalent in *E. coli* ST131 (51, 52), whereas *fimH22* type has been observed in strains from animal populations, increasing the risk of zoonotic transmissions (52). Additionally, 68 different STs were identified. The ST131, ST410 and ST354 were the most common STs associated with a human origin, whereas for animal hosts, ST131 and ST648 were predominant. Our findings confirm previous studies showing predominance of ST10, ST131, ST410, ST648, and ST744 in MDR *E. coli* strains from human and/or animal clinical samples (7). In Brazil, *E. coli* belonging to ST131, ST10, ST69, ST73, ST354, ST405, and ST648 have been reported from human samples (53–54), and ST73, ST10, ST131, ST648 have been recovered from captive and wild birds, poultry, and cats (5, 55, 56). Finally, we identified the ST10 as the predominant ST found in environmental samples, as previously reported in European and Asian countries (57–60). Previous genomic studies have demonstrated a phylogenomic relatedness of ST131, ST58, ST10, ST648 and ST38 from Brazil with international clones of the same STs, denoting successful adaptation of international clones of *E. coli* at the human-animal-environment interface, in Brazil (5, 61–65).

The establishment of high-risk clones overlapping human and nonhuman sources offers the opportunity to successfully disseminate resistance genes that makes difficult the control this situation (9, 10, 60). Under this perspective, other factors that drive antibiotic resistance deserve attention, such as overuse of antibiotics in multiple sectors to treat infections or for agriculture purposes, poor implementation of hygiene and sanitization actions, and the environmental contamination by inappropriate waste treatment (3). These aspects provide a snapshot of the need to enforce a comprehensive One Health strategy that considers the connection of human, animal, and environmental health in order to preserve the effectiveness of currently available antibiotics (3).

In general, over the last decades, there has been a significant increase in antibiotic prescribing and consumption leading bacterial resistance to the point of becoming a global priority (66). During COVID-19 pandemic use of antibiotics and biocide has grown even more rapidly (66, 67), which can strongly favor the selection and dissemination of WHO critical priority resistant pathogens at the human-animal interface (68). In fact, an increase in the incidence of antimicrobial resistance has been documented during COVID-19 pandemic (69, 70), with a rapid increase in multidrug-resistant organisms, including extended-spectrum β -lactamase (ESBL)-producing and/or carbapenem-resistant NDM-producing Enterobacterales, *A. baumannii*, and methicillin-resistant *Staphylococcus aureus* (MRSA). The cause has been multifactorial and is particularly related to high rates of antimicrobial agent utilization in COVID-19 patients with a relatively low rate of co- or secondary infection (71). In this regard, household transmission of carbapenemase-producing organisms has been linked to hospital discharge (72), becoming a potential way for transmission of such bacteria to humans and companion animals during the pandemic period (73); since COVID-19 pandemic has increased relationships and interactions between family members, and between humans and pets, supported by widespread social distancing and isolation measures. In Brazil, these facts are particularly worrying, since the prevalence of critical priority ESBL and

carbapenemase producers has been higher than reported in other countries (74, 75). Additionally, in October 2021 an epidemiological alert on emergence and increase of new combinations of carbapenemases in Enterobacterales, triggered by the increased use of broad-spectrum antibiotics in patients with COVID-19, in Latin America and the Caribbean was announced by the Pan American Health Organization (PHAO), emphasizing the importance of appropriate microbiological diagnosis and the effective and articulated implementation of infection prevention and control programs (76).

As a limitation of this study, since short-read sequencing technology was used, it could influence the number of contigs and lead to the missing of resistance, virulence, and plasmid replicon genes in the genomes analyses. In addition, draft genomes may overestimate the number of accessory genes in Roary. We also did not perform a temporal analysis since it was not possible to retrieve strains from every year. Furthermore, we recognized that our study showed an uneven geographic distribution of the analyzed strains because most of them are from the Southeastern region.

In conclusion, we have investigated the genomic background of critical priority *E. coli* strains circulating at the human-animal-environment interface in Brazil, documenting the successful spread of international high-risk clones with a broad antimicrobial resistome, with *bla*_{CTX-M} ESBL and *mcr-1* genes being endemic, and the rapid and worrisome expansion of *bla*_{KPC-2} and *bla*_{NDM-1} carbapenemase genes. We also found clinically relevant virulomes among *E. coli* strains, which together with the broad resistomes could contribute to the pathogenicity. This genetic background of *E. coli* must be a key factor that has contributed to adaptation and dissemination of critical priority clones in human and nonhuman hosts, which is a serious problem that needs urgent actions that includes both stricter surveillance and more judicious use of antimicrobials, under a One Health perspective. Finally, these observations alert us to the worsening of the antimicrobial resistance problem in Brazil, after the COVID-19 pandemic.

MATERIALS AND METHODS

Sequenced isolates and metadata. During a multicentric surveillance study (One Health Brazilian Resistance [OneBR] project, <http://www.onehealthbr.com/>) conducted to characterize the burden of antimicrobial resistance associated with WHO critical priority pathogens in Brazil, we collected 104 *E. coli* strains isolated from different sources (humans, food-producing animals, companion animals, wildlife, polluted environments, and food), over a 10-year period (2010 to 2019). The isolates were obtained from all geographic regions (North, Northeast, Midwest, Southeast and South). From this collection, 54 *E. coli* strains displaying resistance to broad-spectrum cephalosporins, carbapenems, colistin and/or fluoroquinolones, were selected for WGS and investigated in this study.

For comparative genomic analysis, we used 36 *E. coli* genomes previously published and deposited in our platform OneBR (<http://www.onehealthbr.com/>). Additionally, we included 77 publicly available Brazilian *E. coli* genomes deposited at the GenBank database (<https://www.ncbi.nlm.nih.gov/genbank/>). These genomes were chosen based on the resistance profile of each strain, and complete epidemiological information (i.e., source, origin, city, and date of collection). In total, 167 genomes of *E. coli* strains circulating at the human-animal-environment interface, in Brazil, were analyzed in this study. Detailed information is presented in Table S1.

The genomes were clustered in four groups according to their origin (human, animal, environmental, and food). The human group included samples from blood, bone fragment, catheter, feces, urine, fistula fluid, ileum mucosa, prosthesis, rectal swab, and other body fluids (e.g., foot, pelvic, or tracheal secretion). Genomes of *E. coli* isolated from pets (dog and cat), livestock animals (cattle, chicken/poultry, horse, and turkey), and wild animals (anteater, elephant, fish, ocelot, owl, penguin, and vulture) have been obtained from rectal/cloacal sample or different sites of infection. The food group included strains from meat (chicken), crustacean (shrimp), seafood (mussels and oysters), and vegetables (spinach and cabbage); whereas *E. coli* strains recovered from freshwater, seawater, soil, drainage, and directional residue, were included in the environmental group.

Antimicrobial resistance profile. The *Escherichia coli* isolates ($n = 104$) collected in this study were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF), and screened to select MDR profiles (77, 78). For the latter, initially an overnight culture of each strain was grown on MacConkey agar plates, in the absence and presence of ceftriaxone ($2 \mu\text{g/mL}$) or colistin ($2 \mu\text{g/mL}$), at 37°C . Growing colonies were then subjected to antimicrobial susceptibility tests by disk diffusion method using human and veterinary antibiotics, which included ampicillin, amoxicillin/clavulanate, aztreonam, cephalothin, ceftriaxone, cefotaxime, ceftiofur, ceftazidime, cefoxitin, cefepime, ertapenem, imipenem, meropenem, nalidixic acid, ciprofloxacin, enrofloxacin, amikacin, gentamicin, trimethoprim-sulfamethoxazole, chloramphenicol, fosfomicin, and tetracycline. For colistin, susceptibility was determined by the broth microdilution method. Interpretative criteria were based on CLSI and/or EUCAST guidelines (79–81).

Whole-genome sequencing. The genomic DNA of *E. coli* ($n = 54$) strains was sequenced using the Illumina NextSeq (San Diego, USA) platform. In brief, single colonies of each strain were grown in 3 mL of lysogeny broth for 18 h at 37°C, and the DNA was extracted using a PureLink quick gel extraction kit (Life Technologies, CA). NextSeq libraries were constructed using the Nextera DNA Flex library prep (Illumina Inc., San Diego, CA) and sequenced using 2×75 bp paired-end reads. Raw sequencing data were quality filtered to remove low-quality bases (Phred quality < 20) using TrimGalore v0.6.5 (<https://github.com/FelixKrueger/TrimGalore>) or Trimmomatic v0.32 (<https://github.com/timflutre/trimmomatic>). Quality-filtered reads were *De novo* assembled using Unicycler v0.4.8 (<https://github.com/rwwick/Unicycler>) assembler with default parameters (82). Contigs with less than 200-bp long were removed from the genome.

Genome data analysis. Genomic analyses of sequenced *E. coli* strains, and publicly available genomes ($n = 113$) were performed using the ResFinder v4.1, VirulenceFinder v2.0, KmerFinder v3.1, PlasmidFinder v2.0, pMLST v2.0, MLST v2.0, SerotypeFinder v2.0 and FimTyper v1.0 tools from CGE (<http://genomepidemiology.org/>) (83–88). ABRicate v0.9.8 (<https://github.com/tseemann/abricate>) was also used to predict virulence genes profiling through the VFDB database (<https://github.com/haruosuz/vfdb>). Threshold ID and minimum length values (identity and coverage) of $\geq 90\%$ were used for all database scanning. Plasmids with identity greater than 98% were categorized into different incompatibility (Inc.) groups. The *E. coli* phylogroup was performed using ClermonTyping v1.4.0 (89). Heavy metal (HM, arsenic, silver, tellurium, lead, and mercury) and disinfectants (QACs) resistance genes were screened using the BacMet2 database (<http://bacmet.biomedicine.gu.se>) and ABRicate v0.9.8. Additionally, pesticide (glyphosate) resistance genes were identified by *in silico* comparative analysis using an in-house database.

The genomes submitted to NCBI were annotated using the NCBI Prokaryotic Genome Annotation Pipeline v3.2 (http://www.ncbi.nlm.nih.gov/genome/annotation_prok/).

To assess the phylogenomic relationship of *E. coli* strains under a One Health approach, 167 draft genomes from human and nonhumans strains, collected in several regions of Brazil, were analyzed. The analysis of the *E. coli* pangenome was accessed by Roary pipeline version 3.13.0 (90) using annotated draft assemblies in GFF3 format produced by Prokka (91). The gene presence/absence output from Roary was used to construct the pangenome gene presence-absence matrix that was visualized using Roary.plots.py program. The core gene alignment was used to construct the phylogenetic structure of *E. coli* strains. SNPs (single nucleotide polymorphism) were extracted from the core gene alignment using SNP-sites (92) and a maximum likelihood tree based on SNP alignment was constructed using RAxML-NG version 0.9.0 under the generalized time-reversible model with gamma-distributed rate heterogeneity (93). The phylogeny was tested against 100 bootstrap replications and the resulting tree was visualized with iTOL version 5.6.1 (94). The percent identity was automatically calculated from the core gene alignment by SNP-sites and a table generated from the Geneious software. Metadata of *E. coli* strains have been made freely publicly available for interactive exploration through Microreact (<https://microreact.org/project/noM6Wi46mnpdYSzENnWmKX>) (95). In addition to the general analysis of the strains ($n = 167$), the most represented pandemic clones (ST10, ST38, ST131, ST354, ST410, ST648, and ST744) were also analyzed separately.

Data availability. The data sets analyzed during the current study are available in the GenBank (<https://www.ncbi.nlm.nih.gov/genbank>) and corresponding access numbers are described in supplementary information (Table S1). Additionally, data are also available at the OneBR platform (<http://onehealthbr.com>).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.4 MB.

SUPPLEMENTAL FILE 2, XLSX file, 0.1 MB.

SUPPLEMENTAL FILE 3, XLSX file, 0.2 MB.

SUPPLEMENTAL FILE 4, XLSX file, 0.03 MB.

ACKNOWLEDGMENTS

We thank Cefar Diagnóstica Ltda (São Paulo, Brazil) and CEFAP-GENIAL facility for kindly supplying antibiotic disks for susceptibility testing and Illumina sequencing, respectively. We additionally thank Danny Fuentes-Castillo, Meire Silva, Luana Melo, Miriam R. Fernandes, Flávio Oliveira, Marcelo Carvalho, Luciana Sartori, and Daniel Monte for the help and/or availability of the published genomes included in One Health Brazilian Resistance project (<http://www.onehealthbr.com/>).

B.F. and N.L. conceived the study design and writing original draft. B.F. performed all experiments. B.F., F.E., B.C., Q.M., and A.C.-A. carried out the experimental work (DNA extractions and/or sequencing library preparations). B.F., L.C., H.F., and E.S. performed sequencing data analysis. F.P.S. contributed to analysis and literature review. R.M.R., A.C.C., M.C.B.T., M.M.C.M., A.J.P.G.Q., A.P.S., J.N.R., M.P., E.C.V., A.M.F.C., and T.C.M.S. provided strains and data collection. All authors provided the critical revision, contributed to the final writing of the manuscript, and approved the submission.

Bill and Melinda Gates Foundation, Grand Challenges Explorations Brazil—New approaches to characterize the global burden of antimicrobial resistance [grant OPP1193112], Conselho Nacional de Desenvolvimento Científico e Tecnológico [grants AMR 443819/2018-1, 433128/2018-6, and 312249/2017-9], Fundação de Amparo à Pesquisa do Estado de São Paulo [grant 2020/08224-9 and 2019/15578-4], and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [grants 88887.358057/2019-00 and 1794306] are gratefully acknowledged. N.L. is a research fellow of CNPq [grant 314336/2021-4].

We declare that they have no competing interests.

REFERENCES

- Munita JM, Arias CA. 2016. Mechanisms of antibiotic resistance. *Microbiol Spectr* 4. <https://doi.org/10.1128/microbiolspec.VMBF-0016-2015>.
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, WHO Pathogens Priority List Working Group. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *Lancet Infect Dis* 18:318–327. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3).
- McEwen SA, Collignon PJ. 2018. Antimicrobial resistance: a One Health perspective. *Microbiol Spectr* 6. <https://doi.org/10.1128/microbiolspec.ARBA-0009-2017>.
- World Health Organization (WHO). 2019. Highest priority critically important antimicrobials. <https://www.who.int/foodsafety/cia/en/>.
- Fernandes MR, Sellera FP, Moura Q, Gaspar VC, Cerdeira L, Lincopan N. 2018. International high-risk clonal lineages of CTX-M-producing *Escherichia coli* F-ST648 in free-roaming cats, South America. *Infect Genet Evol* 66:48–51. <https://doi.org/10.1016/j.meegid.2018.09.009>.
- Roer L, Overballe-Petersen S, Hansen F, Schønning K, Wang M, Røder BL, Hansen DS, Justesen US, Andersen LP, Fulgsang-Damgaard D, Hopkins KL, Woodford N, Falgenhauer L, Chakraborty T, Samuelsen Ø, Sjöström K, Johannesen TB, Ng K, Nielsen J, Ethelberg S, Stegger M, Hammerum AM, Hasman H. 2018. *Escherichia coli* sequence type 410 is causing new international high-risk clones. *mSphere* 3:e00337-18. <https://doi.org/10.1128/mSphere.00337-18>.
- Mbelle NM, Feldman C, Sekyere JO, Maningi NE, Modipane L, Essack SY. 2019. The Resistome, mobilome, virulome and phylogenomics of multidrug-resistant *Escherichia coli* clinical isolates from Pretoria, South Africa. *Sci Rep* 9:16457. <https://doi.org/10.1038/s41598-019-52859-2>.
- Ludden C, Raven KE, Jamroz D, Gouliouris T, Blane B, Coll F, de Goffau M, Naydenova P, Horner C, Hernandez-Garcia J, Wood P, Hadjirin N, Radakovic M, Brown NM, Holmes M, Parkhill J, Peacock SJ. 2019. One Health genomic surveillance of *Escherichia coli* demonstrates distinct lineages and mobile genetic elements in isolates from humans versus livestock. *mBio* 10:e02693-18. <https://doi.org/10.1128/mBio.02693-18>.
- Mathers AJ, Peirano G, Pitout JD. 2015. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. *Clin Microbiol Rev* 28:565–591. <https://doi.org/10.1128/CMR.00116-14>.
- Hernando-Amado S, Coque TM, Baquero F, Martínez JL. 2019. Defining and combating antibiotic resistance from One Health and global health perspectives. *Nat Microbiol* 4:1432–1442. <https://doi.org/10.1038/s41564-019-0503-9>.
- IBGE (Instituto Brasileiro de Geografia e Estatística). 2017. Data from "Atlas Geográfico e Escolar". População total - 2017. https://atlascolar.ibge.gov.br/images/atlas/mapas_mundo/mundo_populacao_total.pdf. Accessed Nov, 2021.
- Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat. 2020. World population prospects: the 2019 revision. <https://population.un.org/wpp/Download/Standard/Population/>.
- Butler R, Rainforest Facts for 2020. Data from "Rainforest Facts for 2021". <https://rainforests.mongabay.com/facts/rainforest-facts.html>.
- ministry of agriculture, livestock and food supply (mapa). 2017. the brazilian meat industry: production and inspection. <http://www.brazil.gov.br/about-brazil/news/2017/03/factsheet-carne-english.pdf/@download/file/FactSheet-Carne%20ENGLISH.pdf>.
- Oliveira U, Soares-Filho BS, Paglia AP, Brescovit AD, de Carvalho CJB, Silva DP, Rezende DT, Leite FSF, Batista JAN, Barbosa JPPP, Stehmann JR, Ascher JS, de Vasconcelos MF, De Marco P, Löwenberg-Neto P, Ferro VG, Santos AJ. 2017. Biodiversity conservation gaps in the Brazilian protected areas. *Sci Rep* 7:9141. <https://doi.org/10.1038/s41598-017-08707-2>.
- Magnusson WE, Grelle CEV, Marques MCM, Rocha CFD, Dias B, Fontana CS, Bergallo H, Overbeck GE, Vale MM, Tomas WM, Cerqueira R, Collevatti R, Pillar VD, Malabarba LR, Lins-e-Silva AC, Neckel-Oliveira S, Martinelli B, Akama A, Rodrigues D, Silveira LF, Scariot A, Fernandes GW. 2018. Effects of Brazil's political crisis on the science needed for biodiversity conservation. *Front Ecol Evol* 6:163. <https://doi.org/10.3389/fevo.2018.00163>.
- Vila J, Sáez-López E, Johnson JR, Römmling U, Dobrindt U, Cantón R, Giske CG, Naas T, Carattoli A, Martínez-Medina M, Bosch J, Retamar P, Rodríguez-Baño J, Baquero F, Soto SM. 2016. *Escherichia coli*: an old friend with new tidings. *FEMS Microbiol Rev* 40:437–463. <https://doi.org/10.1093/femsre/fuw005>.
- Collignon P, Beggs JJ, Walsh TR, Gandra S, Laxminarayan R. 2018. Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and multivariable analysis. *Lancet Planet Health* 2:e398–e405. [https://doi.org/10.1016/S2542-5196\(18\)30186-4](https://doi.org/10.1016/S2542-5196(18)30186-4).
- Adator EH, Narvaez-Bravo C, Zaheer R, Cook SR, Tymensen L, Hannon SJ, Booker CW, Church D, Read RR, McAllister TA. 2020. A One Health comparative assessment of antimicrobial resistance in generic and extended-spectrum cephalosporin-resistant *Escherichia coli* from beef production, sewage and clinical settings. *Microorganisms* 8:885. <https://doi.org/10.3390/microorganisms8060885>.
- Hosuru Subramanya S, Bairy I, Nayak N, Amberpet R, Padukone S, Metok Y, Bhatta DR, Sathian B. 2020. Detection and characterization of ESBL-producing Enterobacteriaceae from the gut of healthy chickens, *Gallus gallus domesticus* in rural Nepal: dominance of CTX-M-15-non-ST131 *Escherichia coli* clones. *PLoS One* 15:e0227725. <https://doi.org/10.1371/journal.pone.0227725>.
- Monte DF, Mem A, Fernandes MR, Cerdeira L, Esposito F, Galvão JA, Franco BDGM, Lincopan N, Landgraf M. 2017. Chicken meat as a reservoir of colistin-resistant *Escherichia coli* strains carrying *mcr-1* genes in South America. *Antimicrob Agents Chemother* 61:e02718-16. <https://doi.org/10.1128/AAC.02718-16>.
- Kempf I, Jouy E, Chauvin C. 2016. Colistin use and colistin resistance in bacteria from animals. *Int J Antimicrob Agents* 48:598–606. <https://doi.org/10.1016/j.ijantimicag.2016.09.016>.
- Matamoros S, van Hattem JM, Arcilla MS, Willemsse N, Melles DC, Penders J, Vinh TN, Thi Hoa N, Bootsma MCJ, van Genderen PJ, Goorhuis A, Grobusch M, Molhoek N, Oude Lashof AML, Stobberingh EE, Verbrugh HA, de Jong MD, Schultz C. 2017. Global phylogenetic analysis of *Escherichia coli* and plasmids carrying the *mcr-1* gene indicates bacterial diversity but plasmid restriction. *Sci Rep* 7:15364. <https://doi.org/10.1038/s41598-017-15539-7>.
- Vidovic N, Vidovic S. 2020. Antimicrobial resistance and food animals: influence of livestock environment on the emergence and dissemination of antimicrobial resistance. *Antibiotics* 9:52. <https://doi.org/10.3390/antibiotics9020052>.
- Wang R, van Dorp L, Shaw LP, Bradley P, Wang Q, Wang X, Jin L, Zhang Q, Liu Y, Rieux A, Dorai-Schneiders T, Weiernt LA, Iqbal Z, Didelot X, Wang H, Balloux F. 2018. The global distribution and spread of the mobilized colistin resistance gene *mcr-1*. *Nat Commun* 9:1179. <https://doi.org/10.1038/s41467-018-03205-z>.
- Silva MM, Sellera FP, Fernandes MR, Moura Q, Garino F, Azevedo SS, Lincopan N. 2018. Genomic features of a highly virulent, ceftiofur-resistant, CTX-M-8-producing *Escherichia coli* ST224 causing fatal infection in a domestic cat. *J Glob Antimicrob Resist* 15:252–253. <https://doi.org/10.1016/j.jgar.2018.10.023>.
- Stoesser N, Sheppard AE, Peirano G, Anson LW, Pankhurst L, Sebra R, Phan HTT, Kasarskis A, Mathers AJ, Peto TEA, Bradford P, Motyl MR,

- Walker AS, Crook DW, Pitout JD. 2017. Genomic epidemiology of global *Klebsiella pneumoniae* carbapenemase (KPC)-producing *Escherichia coli*. *Sci Rep* 7:5917. <https://doi.org/10.1038/s41598-017-06256-2>.
28. Fernandes MR, Sellera FP, Moura Q, Esposito F, Sabino CP, Lincopan N. 2020. Identification and genomic features of halotolerant extended-spectrum- β -lactamase (CTX-M)-producing *Escherichia coli* in urban-impacted coastal waters, Southeast Brazil. *Mar Pollut Bull* 150:110689. <https://doi.org/10.1016/j.marpolbul.2019.110689>.
 29. Poirel L, Cattoir V, Nordmann P. 2012. Plasmid-mediated quinolone resistance; interactions between human, animal, and environmental ecologies. *Front Microbiol* 3:24. <https://doi.org/10.3389/fmicb.2012.00024>.
 30. Tyson GH, Li C, Hsu CH, Bodeis-Jones S, McDermott PF. 2019. Diverse fluoroquinolone resistance plasmids from retail meat *E. coli* in the United States. *Front Microbiol* 10:2826. <https://doi.org/10.3389/fmicb.2019.02826>.
 31. Kaspersen H, Sekse C, Zeyl Fiskebeck E, Slettemeås JS, Simm R, Norström M, Urdahl AM, Lagesen K. 2020. Dissemination of quinolone-resistant *Escherichia coli* in the Norwegian broiler and pig production chains and possible persistence in the broiler production environment. *Appl Environ Microbiol* 86:e02769-19. <https://doi.org/10.1128/AEM.02769-19>.
 32. Stapleton AE, Wagenlehner FME, Mulgirigama A, Twynholm M. 2020. *Escherichia coli* resistance to fluoroquinolones in community-acquired uncomplicated urinary Tract infection in women: a systematic review. *Antimicrob Agents Chemother* 64:e00862-20. <https://doi.org/10.1128/AAC.00862-20>.
 33. Romero JL, Grande Burgos MJ, Pérez-Pulido R, Gálvez A, Lucas R. 2017. Resistance to antibiotics, biocides, preservatives and metals in bacteria isolated from seafoods: co-selection of strains resistant or tolerant to different classes of compounds. *Front Microbiol* 8:1650. <https://doi.org/10.3389/fmicb.2017.01650>.
 34. Barber OW, Hartmann EM. 2021. Benzalkonium chloride: a systematic review of its environmental entry through wastewater treatment, potential impact, and mitigation strategies. *Crit Rev Environ Sci Technol In Press* 1–30. <https://doi.org/10.1080/10643389.2021.1889284>.
 35. Buffet-Bataillon S, Tattevin P, Maillard JY, Bonnaure-Mallet M, Jolivet-Gougeon A. 2016. Efflux pump induction by quaternary ammonium compounds and fluoroquinolone resistance in bacteria. *Future Microbiol* 11: 81–92. <https://doi.org/10.2217/fmb.15.131>.
 36. Tripathi V, Cytryn E. 2017. Impact of anthropogenic activities on the dissemination of antibiotic resistance across ecological boundaries. *Essays Biochem* 61:11–21. <https://doi.org/10.1042/EBC20160054>.
 37. Denamur E, Clermont O, Bonacorsi S, Gordon D. 2021. The population genetics of pathogenic *Escherichia coli*. *Nat Rev Microbiol* 19:37–54. <https://doi.org/10.1038/s41579-020-0416-x>.
 38. Ewers C, de Jong A, Prenger-Berninghoff E, El Garch F, Leidner U, Tiwari SK, Semmler T. 2021. Genomic diversity and virulence potential of ESBL- and AmpC- β -lactamase-producing *Escherichia coli* strains from healthy food animals across. *Front Microbiol* 12:626774. <https://doi.org/10.3389/fmicb.2021.626774>.
 39. Sánchez F, Fuenzalida V, Ramos R, Escobar B, Neira V, Borie C, Lapiere L, López P, Venegas L, Dettleff P, Johnson T, Fuentes-Castillo D, Lincopan N, Galarce N. 2021. Genomic features and antimicrobial resistance patterns of Shiga toxin-producing *Escherichia coli* strains isolated from food in Chile. *Zoonoses Public Health* 68:226–238. <https://doi.org/10.1111/zph.12818>.
 40. Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, Peirano G, Bonnedahl J, Dolejska M, Literak I, Fuchs S, Ahmed N, Grobbel M, Torres C, McNally A, Pickard D, Ewers C, Croucher NJ, Corander J, Guenther S. 2019. Genomic and functional analysis of emerging virulent and multidrug-resistant *Escherichia coli* lineage sequence type 648. *Antimicrob Agents Chemother* 63:e00243-19. <https://doi.org/10.1128/AAC.00243-19>.
 41. Sarowska J, Futoma-Koloch B, Jama-Kmiecik A, Frej-Madrzak M, Ksiaczek M, Bugla-Ploskonska G, Choroszy-Krol I. 2019. Virulence factors, prevalence and potential transmission of extraintestinal pathogenic *Escherichia coli* isolated from different sources: recent reports. *Gut Pathog* 11:10. <https://doi.org/10.1186/s13099-019-0290-0>.
 42. Searle LJ, Méric G, Porcelli I, Sheppard SK, Lucchini S. 2015. Variation in siderophore biosynthetic gene distribution and production across environmental and faecal populations of *Escherichia coli*. *PLoS One* 10: e0117906. <https://doi.org/10.1371/journal.pone.0117906>.
 43. Su Q, Guan T, Lv H. 2016. Siderophore biosynthesis coordinately modulated the virulence-associated interactive metabolome of uropathogenic *Escherichia coli* and human urine. *Sci Rep* 6:24099. <https://doi.org/10.1038/srep24099>.
 44. Robinson AE, Heffernan JR, Henderson JP. 2018. The iron hand of uropathogenic *Escherichia coli*: the role of transition metal control in virulence. *Future Microbiol* 13:745–756. <https://doi.org/10.2217/fmb-2017-0295>.
 45. Khasheii B, Mahmoodi P, Mohammadzadeh A. 2021. Siderophores: importance in bacterial pathogenesis and applications in medicine and industry. *Microbiol Res* 250:126790. <https://doi.org/10.1016/j.micres.2021.126790>.
 46. Aslani MM, Alikhani MY, Zavari A, Yousefi R, Zamani AR. 2011. Characterization of enteroaggregative *Escherichia coli* (EAEC) clinical isolates and their antibiotic resistance pattern. *Int J Infect Dis* 15:e136–e139. <https://doi.org/10.1016/j.ijid.2010.10.002>.
 47. Saraceno M, Gómez Lugo S, Ortiz N, Gómez BM, Sabio Y García CA, Frankel N, Graziano M. 2021. Unraveling the ecological processes modulating the population structure of *Escherichia coli* in a highly polluted urban stream network. *Sci Rep* 11:14679. <https://doi.org/10.1038/s41598-021-94198-1>.
 48. Fais T, Delmas J, Barnich N, Bonnet R, Dalmaso G. 2018. Colibactin: more than a new bacterial toxin. *Toxins (Basel)* 10:151. <https://doi.org/10.3390/toxins10040151>.
 49. Hazen TH, Mettus R, McElheny CL, Bowler SL, Nagaraj S, Doi Y, Rasko DA. 2018. Diversity among bla_{qPC} -containing plasmids in *Escherichia coli* and other bacterial species isolated from the same patients. *Sci Rep* 8:10291. <https://doi.org/10.1038/s41598-018-28085-7>.
 50. Silva KC, Moreno M, Cabrera C, Spira B, Cerdeira L, Lincopan N, Moreno AM. 2016. First characterization of CTX-M-15-producing *Escherichia coli* strains belonging to sequence type (ST) 410, ST224, and ST1284 from commercial swine in South America. *Antimicrob Agents Chemother* 60: 2505–2508. <https://doi.org/10.1128/AAC.02788-15>.
 51. Matsumura Y, Johnson JR, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S, Kyoto-Shiga Clinical Microbiology Study Group; Kyoto-Shiga Clinical Microbiology Study Group. 2015. CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant *Escherichia coli* of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. *J Antimicrob Chemother* 70:1639–1649. <https://doi.org/10.1093/jac/dkv017>.
 52. Liu CM, Stegger M, Aziz M, Johnson TJ, Waits K, Nordstrom L, Gauld L, Weaver B, Rolland D, Statham S, Horwinski J, Sariya S, Davis GS, Sokurenko E, Keim P, Johnson JR, Price LB. 2018. *Escherichia coli* ST131-H22 as a foodborne uropathogen. *mBio* 9:e00470-18. <https://doi.org/10.1128/mBio.00470-18>.
 53. de Souza da-Silva AP, de Sousa VS, Martins N, da Silva Dias RC, Bonelli RR, Riley LW, Moreira BM. 2017. *Escherichia coli* sequence type 73 as a cause of community acquired urinary tract infection in men and women in Rio de Janeiro, Brazil. *Diagn Microbiol Infect Dis* 88:69–74. <https://doi.org/10.1016/j.diagmicrobio.2017.01.024>.
 54. Campos ACC, Andrade NL, Ferdous M, Chlebawicz MA, Santos CC, Correal JCD, Lo Ten Foe JR, Rosa ACP, Damasco PV, Friedrich AW, Rossen JWA. 2018. Comprehensive molecular characterization of *Escherichia coli* isolates from urine samples of hospitalized patients in Rio de Janeiro. *Brazil Front Microbiol* 9:243. <https://doi.org/10.3389/fmicb.2018.00243>.
 55. Cunha MPV, Saldenberg AB, Moreno AM, Ferreira AJP, Vieira MAM, Gomes TAT, Knöbl T. 2017. Pandemic extra-intestinal pathogenic *Escherichia coli* (ExPEC) clonal group O6-B2-ST73 as a cause of avian colibacillosis in Brazil. *PLoS One* 12:e0178970. <https://doi.org/10.1371/journal.pone.0178970>.
 56. Sellera FP, Fernandes MR, Sartori L, Carvalho MP, Esposito F, Nascimento CL, Dutra GH, Mamizuka EM, Pérez-Chaparro PJ, McCulloch JA, Lincopan N. 2017. *Escherichia coli* carrying IncX4 plasmid-mediated *mcr-1* and *bla*_{CTX-M} genes in infected migratory Magellanic penguins (*Spheniscus magellanicus*). *J Antimicrob Chemother* 72:1255–1256. <https://doi.org/10.1093/jac/dkw543>.
 57. Caltagirone M, Nucleo E, Spalla M, Zara F, Novazzi F, Marchetti VM, Piazza A, Bitar I, De Cicco M, Paolucci S, Pilla G, Migliavacca R, Pagani L. 2017. Occurrence of extended spectrum β -lactamases, KPC-type, and MCR-1.2-producing Enterobacteriaceae from wells, river water, and wastewater treatment plants in Oltrepò Pavese area, Northern Italy. *Front Microbiol* 8: 2232. <https://doi.org/10.3389/fmicb.2017.02232>.
 58. Zhao F, Feng Y, Lü X, McNally A, Zong Z. 2017. Remarkable diversity of *Escherichia coli* carrying *mcr-1* from hospital sewage with the identification of two new *mcr-1* variants. *Front Microbiol* 8:2094. <https://doi.org/10.3389/fmicb.2017.02094>.
 59. Shen C, Feng S, Chen H, Dai M, Paterson DL, Zheng X, Wu X, Zhong LL, Liu Y, Xia Y, Ma R, Huang X, Tian GB. 2018. Transmission of *mcr-1*-producing multidrug-resistant Enterobacteriaceae in public transportation in Guangzhou, China. *Clin Infect Dis* 67:S217–24. <https://doi.org/10.1093/cid/ciy661>.
 60. Woodford N, Turton JF, Livermore DM. 2011. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic

- resistance. *FEMS Microbiol Rev* 35:736–755. <https://doi.org/10.1111/j.1574-6976.2011.00268.x>.
61. Saidenberg ABS, Stegger M, Price LB, Johannesen TB, Aziz M, Cunha MPV, Moreno AM, Knöbl T. 2020. *mcr*-positive *Escherichia coli* ST131-H22 from poultry in Brazil. *Emerg Infect Dis* 26:1951–1954. <https://doi.org/10.3201/eid2608.191724>.
 62. Lopes R, Furlan JPR, Dos Santos LDR, Gallo IFL, Stehling EG. 2021. Colistin-resistant *mcr*-1-positive *Escherichia coli* ST131-H22 carrying *bla*_{CTX-M-15} and *qnrB19* in agricultural soil. *Front Microbiol* 12:659900. <https://doi.org/10.3389/fmicb.2021.659900>.
 63. Fuentes-Castillo D, Navas-Suárez PE, Gondim MF, Esposito F, Sacristán C, Fontana H, Fuga B, Piovani C, Kooij R, Lincopan N, Catão-Dias JL. 2021. Genomic characterization of multidrug-resistant ESBL-producing *Escherichia coli* ST58 causing fatal colibacillosis in critically endangered Brazilian merganser (*Mergus octosetaceus*). *Transbound Emerg Dis* 68:258–266. <https://doi.org/10.1111/tbed.13686>.
 64. Ali A, Fontana H, Sano E, Li R, Humayon M, Rahman S, Lincopan N, Mohsin M. 2021. Genomic features of a high-risk *mcr*-1.1-positive *Escherichia coli* ST10 isolated from cattle farm environment. *Environ Sci Pollut Res Int* 28:54147–54152. <https://doi.org/10.1007/s11356-021-15437-6>.
 65. Lopes R, Fuentes-Castillo D, Fontana H, Rodrigues L, Dantas K, Cerdeira L, Henriques I, Lincopan N. 2021. Endophytic lifestyle of global clones of extended-spectrum β -lactamase-producing priority pathogens in fresh vegetables: a Trojan Horse strategy favoring human colonization? *mSystems* 6:e01125-20. <https://doi.org/10.1128/mSystems.01125-20>.
 66. Al-Hadidi SH, Alhussain H, Abdel Hadi H, Johar A, Yassine HM, Al Thani AA, Eltai NO. 2021. The spectrum of antibiotic prescribing during COVID-19 pandemic: a systematic literature review. *Microb Drug Resist* in Press. <https://doi.org/10.1089/mdr.2020.0619>.
 67. Ruiz J. 2021. Enhanced antibiotic resistance as a collateral COVID-19 pandemic effect? *J Hosp Infect* 107:114–115. <https://doi.org/10.1016/j.jhin.2020.11.010>.
 68. Rossato L, Negrão FJ, Simionatto S. 2020. Could the COVID-19 pandemic aggravate antimicrobial resistance? *Am J Infect Control* 48:1129–1130. <https://doi.org/10.1016/j.ajic.2020.06.192>.
 69. Perez S, Innes GK, Walters MS, Mehr J, Arias J, Greeley R, Chew D. 2020. Increase in hospital-acquired carbapenem-resistant *Acinetobacter baumannii* infection and colonization in an acute care hospital during a surge in COVID-19 admissions - New Jersey, February-July 2020. *MMWR Morb Mortal Wkly Rep* 69:1827–1831. <https://doi.org/10.15585/mmwr.mm6948e1>.
 70. Baiou A, Elbuzidi AA, Bakdach D, Zaout A, Alarbi KM, Bintaher AA, Ali MMB, Elarabi AM, Ali GAM, Daghfal J, Almaslamani MA, Ibrahim ASS, Alkhal A, Omrani AS. 2021. Clinical characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative bacteria from critically ill patients with COVID-19. *J Hosp Infect* 110:165–171. <https://doi.org/10.1016/j.jhin.2021.01.027>.
 71. Lai CC, Chen SY, Ko WC, Hsueh PR. 2021. Increased antimicrobial resistance during the COVID-19 pandemic. *Int J Antimicrob Agents* 57:106324. <https://doi.org/10.1016/j.ijantimicag.2021.106324>.
 72. Marimuthu K, Mo Y, Ling ML, Hernandez-Koutoucheva A, Fenlon SN, Bertrand D, Lye DC, Ang BSP, Perencevich E, Ng OT, Cooper BS, Nagarajan N, Chen SL, Barkham T. 2021. Household transmission of carbapenemase-producing *Enterobacteriaceae*: a prospective cohort study. *J Antimicrob Chemother* 76:1299–1302. <https://doi.org/10.1093/jac/dkaa561>.
 73. Sellera FP, Da Silva LCBA, Lincopan N. 2021. Rapid spread of critical priority carbapenemase-producing pathogens in companion animals: a One Health challenge for a post-pandemic world. *J Antimicrob Chemother* in Press. <https://doi.org/10.1093/jac/dkab169>.
 74. Rossi F. 2011. The challenges of antimicrobial resistance in Brazil. *Clin Infect Dis* 52:1138–1143. <https://doi.org/10.1093/cid/cir120>.
 75. Sampaio JL, Gales AC. 2016. Antimicrobial resistance in Enterobacteriaceae in Brazil: focus on β -lactams and polymyxins. *Braz J Microbiol* 47 Suppl 1:31–37. <https://doi.org/10.1016/j.bjm.2016.10.002>.
 76. Pan American Health Organization. 2021. Epidemiological Alert: Emergence and increase of new combinations of carbapenemases in Enterobacteriales in Latin America and the Caribbean. <https://www.paho.org/en/documents/epidemiological-alert-emergence-and-increase-new-combinations-carbapenemases>. Accessed Nov 12, 2021.
 77. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 18:268–281. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
 78. Singhal N, Kumar M, Kanaujia PK, Viridi JS. 2015. MALDI-TOF mass spectrometry: an emerging technology for microbial identification and diagnosis. *Front Microbiol* 6:791. <https://doi.org/10.3389/fmicb.2015.00791>.
 79. Clinical and Laboratory Standards Institute (CLSI). 2021. Performance standards for antimicrobial susceptibility testing. Thirty-first Informational Supplement M100-S31, CLSI, Wayne, PA.
 80. Clinical and Laboratory Standards Institute (CLSI). 2020. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Fifth Informational Supplement VET01S, CLSI, Wayne, PA.
 81. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2021. Breakpoint tables for interpretation of MICs and zone diameters. Version 11. http://www.eucast.org/clinical_breakpoints/.
 82. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput Biol* 13:e1005595. <https://doi.org/10.1371/journal.pcbi.1005595>.
 83. Carattoli A, Hasman H. 2020. PlasmidFinder and in silico pMLST: identification and typing of plasmid replicons in whole-genome sequencing (WGS). *Methods Mol Biol* 2075:285–294. https://doi.org/10.1007/978-1-4939-9877-7_20.
 84. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, Madden TL. 2009. BLAST+: architecture and applications. *BMC Bioinformatics* 10:421. <https://doi.org/10.1186/1471-2105-10-421>.
 85. Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O, Aarestrup FM, Larsen MV. 2012. Identification of acquired antimicrobial resistance genes. *J Antimicrob Chemother* 67:2640–2644. <https://doi.org/10.1093/jac/dks261>.
 86. Larsen MV, Cosentino S, Rasmussen S, Friis C, Hasman H, Marvig RL, Jelsbak L, Sicheritz-Pontén T, Ussery DW, Aarestrup FM, Lund O. 2012. Multilocus sequence typing of total genome sequenced bacteria. *J Clin Microbiol* 50:1355–1361. <https://doi.org/10.1128/JCM.06094-11>.
 87. Hasman H, Saputra D, Sicheritz-Pontén T, Lund O, Svendsen CA, Frimodt-Møller N, Aarestrup FM. 2014. Rapid whole-genome sequencing for detection and characterization of microorganisms directly from clinical samples. *J Clin Microbiol* 52:139–146. <https://doi.org/10.1128/JCM.02452-13>.
 88. Joensen KG, Tetzschner AM, Iguchi A, Aarestrup FM, Scheutz F. 2015. Rapid and easy in silico serotyping of *Escherichia coli* using whole genome sequencing (WGS) data. *J Clin Microbiol* 53:2410–2426. <https://doi.org/10.1128/JCM.00008-15>.
 89. Beghain J, Bridier-Nahmias A, Le Nagard H, Denamur E, Clermont O. 2018. ClermonTyping: an easy-to-use and accurate in silico method for *Escherichia coli* strain phylogeny. *Microb Genom* 4:e000192. <https://doi.org/10.1099/mgen.0.000192>.
 90. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MT, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 31:3691–3693. <https://doi.org/10.1093/bioinformatics/btv421>.
 91. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
 92. Page AJ, Taylor B, Delaney AJ, Soares J, Seemann T, Keane JA, Harris SR. 2016. SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments. *Microb Genom* 2:e000056. <https://doi.org/10.1099/mgen.0.000056>.
 93. Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A. 2019. RAxML-NG: a fast, scalable, and user-friendly tool for maximum likelihood phylogenetic inference. *Bioinformatics* 35:4453–4455. <https://doi.org/10.1093/bioinformatics/btz305>.
 94. Letunic I, Bork P. 2011. Interactive Tree Of Life v2: online annotation and display of phylogenetic trees made easy. *Nucleic Acids Res* 39:W475–8. <https://doi.org/10.1093/nar/gkr201>.
 95. Argimón S, Abudahab K, Goater RJE, Fedosejev A, Bhai J, Glasner C, Feil EJ, Holden MTG, Yeats CA, Grundmann H, Spratt BG, Aanensen DM. 2016. Microreact: visualizing and sharing data for genomic epidemiology and phylogeography. *Microb Genom* 302:e000093. <https://doi.org/10.1099/mgen.0.000093>.